Inventor · disambiguated record
Yan Lou
Also filed as: LOU YAN · LOU YAN-RU
72 granted patents·23 pending applications·577 citations·filing 2005–2025
99Inventor score
Files withNIKANG THERAPEUTICS INC24NEWAVE PHARMACEUTICAL INC18HOFFMANN LA ROCHE12DEWDNEY NOLAN JAMES6NOVARTIS AG6
Top patents by PatentIndex Score
95 records- 0197US11365206B2BCL-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2020·Granted Jun 21, 2022·7 cites·30 claims
- 0297US11267782B2Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2α inhibitorsNIKANG THERAPEUTICS INC·Filed 2021·Granted Mar 8, 2022·6 cites·26 claims
- 0397US11034705B2Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitorsNIKANG THERAPUETICS INC·Filed 2020·Granted Jun 15, 2021·29 cites·58 claims
- 0497US7902197B2Pyrrolopyrazine kinase inhibitorsROCHE PALO ALTO LLC·Filed 2009·Granted Mar 8, 2011·106 cites·23 claims
- 0596US11993610B2BCL-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2022·Granted May 28, 2024·3 cites·20 claims
- 0696US11827656B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2021·Granted Nov 28, 2023·2 cites·27 claims
- 0796US11753366B2Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitorsNIKANG THERAPEUTICS INC·Filed 2022·Granted Sep 12, 2023·3 cites·6 claims
- 0896US11680072B2Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseasesNEWAVE PHARMACEUTICAL INC·Filed 2022·Granted Jun 20, 2023·4 cites·3 claims
- 0996US11420936B2Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseasesNIKANG THERAPEUTICS INC·Filed 2022·Granted Aug 23, 2022·2 cites·15 claims
- 1096US11279711B2Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseasesNEWAVE PHARMACEUTICAL INC·Filed 2020·Granted Mar 22, 2022·6 cites·21 claims
- 1195US10377755B2BCL-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2018·Granted Aug 13, 2019·11 cites·13 claims
- 1295US7939531B2Pyrrolopyrazine kinase inhibitorsRoche Palo Alto·Filed 2009·Granted May 10, 2011·61 cites·32 claims
- 1395US7932254B2Pyrrolopyrazine kinase inhibitorsRoche Palo Alto·Filed 2009·Granted Apr 26, 2011·60 cites·47 claims
- 1494US10894797B2Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitorsNIKANG THERAPUETICS INC·Filed 2020·Granted Jan 19, 2021·3 cites·30 claims
- 1594US9242969B2Biaryl amide compounds as kinase inhibitorsNOVARTIS AG·Filed 2014·Granted Jan 26, 2016·35 cites·17 claims
- 1694US7902194B2Inhibitors of bruton's tyrosine kinaseRoche Palo Alto·Filed 2009·Granted Mar 8, 2011·33 cites·7 claims
- 1793US11634382B2Process of preparing 3-fluoro-5(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrileNIKANG THERAPEUTICS INC·Filed 2021·Granted Apr 25, 2023·2 cites·37 claims
- 1893US11225493B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Jan 18, 2022·4 cites·32 claims
- 1993US7906509B2Inhibitors of bruton's tyrosine kinaseROCHE PALO ALTO LLC·Filed 2009·Granted Mar 15, 2011·26 cites·21 claims
- 2092US12410190B2Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseasesNEWAVE PHARMACEUTICAL INC·Filed 2023·Granted Sep 9, 2025·1 cites·12 claims
- 2192US10239872B2Therapeutic agents for the treatment of HBV infectionNEWAVE PHARMACEUTICAL INC·Filed 2018·Granted Mar 26, 2019·5 cites·3 claims
- 2292US8124604B2Inhibitors of bruton's tyrosine kinaseDEWDNEY NOLAN JAMES·Filed 2011·Granted Feb 28, 2012·22 cites·23 claims
- 2391US7683064B2Inhibitors of Bruton's tyrosine kinaseROCHE PALO ALTO LLC·Filed 2009·Granted Mar 23, 2010·22 cites·19 claims
- 2490US7943618B2Btk protein kinase inhibitorsROCHE PALO ALTO LLC·Filed 2008·Granted May 17, 2011·18 cites·8 claims
- 2589US10709712B2Biaryl amide compounds as kinase inhibitorsNOVARTIS AG·Filed 2019·Granted Jul 14, 2020·3 cites·7 claims
- 2689US8324211B2Inhibitors of bruton's tyrosine kinaseDEWDNEY NOLAN JAMES·Filed 2009·Granted Dec 4, 2012·14 cites·6 claims
- 2787US11518772B2Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitorsNIKANG THERAPEUTICS INC·Filed 2020·Granted Dec 6, 2022·1 cites·10 claims
- 2887US2025179090A1Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseasesNEWAVE PHARMACEUTICAL INC·Filed 2024·Application pending·0 cites
- 2987US2025340508A1Tetrahydro-1h-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitorsNIKANG THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3086US8318719B2Inhibitors of Bruton's tyrosine kinaseDEWDNEY NOLAN JAMES·Filed 2010·Granted Nov 27, 2012·12 cites·37 claims
- 3186US2024425520A1Bcl-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2024·Application pending·0 cites
- 3285US12391642B2Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitorsNIKANG THERAPEUTICS INC·Filed 2023·Granted Aug 19, 2025·0 cites·19 claims
- 3385US11154563B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Oct 26, 2021·2 cites·28 claims
- 3485US8299077B2Inhibitors of Bruton's tyrosine kinaseBERTHEL STEVEN·Filed 2010·Granted Oct 30, 2012·19 cites·24 claims
- 3584US10245267B2Biaryl amide compounds as kinase inhibitorsNOVARTIS AG·Filed 2017·Granted Apr 2, 2019·3 cites·4 claims
- 3684US9694016B2Biaryl amide compounds as kinase inhibitorsNOVARTIS AG·Filed 2014·Granted Jul 4, 2017·5 cites·8 claims
- 3783US11459340B2Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitorsNIKANG THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·1 cites·8 claims
- 3883US8889682B2Inhibitors of bruton'S tyrosine kinaseBROTHERTON-PLEISS CHRISTINE E·Filed 2012·Granted Nov 18, 2014·8 cites·10 claims
- 3982US10167279B2Compounds and compositions as RAF kinase inhibitorsNOVARTIS AG·Filed 2015·Granted Jan 1, 2019·3 cites·17 claims
- 4082US8822457B2Inhibitors of bruton's tyrosine kinaseROCHE PALO ALTO LLC·Filed 2013·Granted Sep 2, 2014·4 cites·6 claims
- 4181US12264167B2Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitorsNIKANG THERAPEUTICS INC·Filed 2022·Granted Apr 1, 2025·0 cites·11 claims
- 4281US10501456B2Therapeutic agents for the treatment of HBV infectionNEWAVE PHARMACEUTICAL INC·Filed 2019·Granted Dec 10, 2019·1 cites·7 claims
- 4381US2025361203A1Processes of making 3-fluoro-5-(((1s,2ar)-1,3,3,4,4 pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h-cyclopenta[cd]inden-7-yl)oxy)benzonitrile and polymorphs thereofNIKANG THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4481US2025051329A1Bcl-2 inhibitorsNEWAVE PHARMACEUTICAL INC·Filed 2024·Application pending·0 cites
- 4580US10253029B2Dual-warhead covalent inhibitors of FGFR-4NEWAVE PHARMACEUTICAL INC·Filed 2017·Granted Apr 9, 2019·2 cites·19 claims
- 4680US8618098B2Inhibitors of bruton's tyrosine kinaseDEWDNEY NOLAN JAMES·Filed 2012·Granted Dec 31, 2013·4 cites·6 claims
- 4779US8940741B2Inhibitors of bruton's tyrosine kinaseHOFFMANN LA ROCHE·Filed 2013·Granted Jan 27, 2015·4 cites·19 claims
- 4878US12435034B2Process of preparing 3-fluoro-5(((1R,2AR)-3,3,4,4-tetrafluoro-1,2A-dihydroxy-2,2A,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrileNIKANG THERAPEUTICS INC·Filed 2023·Granted Oct 7, 2025·0 cites·20 claims
- 4978US12312370B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2023·Granted May 27, 2025·0 cites·20 claims
- 5077US12415779B2Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereofNIKANG THERAPEUTICS INC·Filed 2022·Granted Sep 16, 2025·0 cites·34 claims
Showing the top 50 of 95 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Yan Lou files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →